Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.72% | 34.62% | 62.54% | 30.00% | 56.16% |
| Total Depreciation and Amortization | 18.09% | -2.29% | 3.52% | -1.59% | -11.69% |
| Total Amortization of Deferred Charges | 14.58% | -- | -- | -- | -4.27% |
| Total Other Non-Cash Items | 11.19% | 185.17% | 26.14% | -70.49% | -10.59% |
| Change in Net Operating Assets | 138.06% | -67.94% | -195.00% | 182.64% | -300.02% |
| Cash from Operations | 191.95% | 104.08% | 87.37% | 86.34% | -103.24% |
| Capital Expenditure | -866.79% | 88.79% | -1,237.49% | -242.50% | -702.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.02% |
| Cash from Investing | -864.43% | 88.79% | -852.34% | -109.52% | -105.72% |
| Total Debt Issued | -- | -- | -- | -- | 100.00% |
| Total Debt Repaid | -131.90% | -133.68% | -94.57% | -10.05% | -7.75% |
| Issuance of Common Stock | -31.24% | -84.68% | 3,315.89% | -34.77% | 1,006.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10,595.36% | -90.34% | 399.84% | -194.84% | 101.42% |
| Foreign Exchange rate Adjustments | -108.00% | 198.43% | -1,354.50% | -303.90% | 394.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 227.38% | -86.94% | 59.09% | 43.91% | -33.03% |